Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • DoP upholds NPPA...

DoP upholds NPPA ceiling price fixation for Azoran 50mg tablet

Farhat NasimWritten by Farhat Nasim Published On 2024-11-05T18:10:42+05:30  |  Updated On 5 Nov 2024 6:10 PM IST
ASCI Flags 233 Health Ads for DMR Act Violation, Reports to AYUSH Ministry
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: The Department of Pharmaceuticals (DoP) has upheld the ceiling price for Azathioprine 50mg tablets, as determined by the National Pharmaceutical Pricing Authority (NPPA) in January 2023. The decision follows a review application filed by RPG Life Sciences Limited, which contested the NPPA's price fixation order regarding the immunosuppressant drug.

The NPPA's original order, issued on January 6, 2023, fixed the ceiling price for the Azoran 50mg tablet pack, which contains Azathioprine, a medication primarily used for treating autoimmune diseases such as multiple sclerosis. RPG Life Sciences argued that the NPPA had incorrectly included a discontinued 10-tablet pack in its price calculations, asserting that the 20-tablet pack was the only product still being marketed since May 2021.

The Mumbai-based drug maker contended that NPPA erred in determining ceiling price of the said drug and should be directed to revise the same.

The drug maker stated that the formulation "Azathioprine 50mg" was included in Schedule-I of DPCO, 2013 with effect from 11 November, 2022, and hence, the formulation "Azoran 50mg Tablet 10's" was also included in the draft calculation of ceiling price released by NPPA on December 1, 2022 under the provisions of Para 4, 6, 10, I l, 14, 16, 17 and 18 of DPCO 2013. The pharma firm stated that it submitted the representation in the prescribed format with required documents and within the prescribed time lines of 10 workings days to NPPA.

Also Read: DoP rejects Glenmark's appeal on price cap of Clotrimazole Cream

RPG Life maintained that in view of the representation from IPC and medical community at large, the pack size of the said formulation was revised from 10' s to 20's pack. Also, that it has never changed the formulation and did not sell 10’s and 20's pack simultaneously in the market. Further, no batches of Azoran 10's was manufactured on or after May 2021. Therefore, NPPA has erred by including their discontinued formulation "Azoran 50mg Tablet 10' s" in its calculation of ceiling price for "Azathioprine 50mg" tablets.

“As per Para 4 of the DPCO 2013, the average Price to Retailer (PTR) is based on the total number of brands of generic version the medicine. The said formulation was only sold in a single brand namely Azoran 50mg. As the change in pack size is not mentioned in Para 4, when considering the price to retailer of the brand as on July 2022, the only price to be considered is of the continuing pack i.e. 20's,” the pharma firm said.

“Hence, the calculation of Azoran 50mg tablet 10’s tablet is incorrect and must be rectified after removing the PTR of their erstwhile brand "Azoran 50mg Tablet 10's",” the drugmaker added.

NPPA on the other side argued that the instant review is not tenable as it considered Pharmatrac database of July, 2022 for calculation of ceiling prices. As per this data, while Azoran 50mg tablet in pack size of 20 had 54.10% market share, its pack size of 10 tablets also had a market share of 26.30%. The confirmation regarding the accuracy of the data was received from the Pharmatrac on April 17, 2023.

Further, the argument that as per Para 4, only continuing pack sizes were to be considered was incorrect. Para 4 (methodology to fix ceiling price) and Para 9 (Reference data & source of market based data) does not differentiate between continuing and discontinued packs. Therefore, NPPA has taken data as per the provision of DPCO for ceiling price calculation of the above mentioned formulation as available in market based data i.e. Pharmatrac and fixed the ceiling price, based on PTR of brands under Para 4 of DPCO, 2013.

Examining the matter, the Department noted that Para 9(5) of DPCO 2013 states that, "The market based data for fixing the ceiling price of a scheduled formulation due to a revision in the first schedule shall be the data available for the month ending immediately before six months of notification of revision in the first schedule. " It nowhere differentiates between continued and discontinued products.

DoP observed;

“The Applicant did not dispute the fact that both of the pack sizes of the said formulation i.e., Azoran 50mg tablet, were available in the market in July 2022, which were captured by the Pharmatrac data and accordingly considered by NPPA for ceiling price calculation. Accordingly, NPPA had used the same for ceiling price calculation of the drugs being considered in the present case as per the provisions of DPCO, 2013.”

Subsequently, the Department said;

“The action of NPPA fixing the ceiling prices of the formulation Azathioprine 50mg vide S.O. No. 87(E) dated 06.01.2023 is upheld and the present Review Application is rejected.”
department of pharmaceuticalsdopceiling priceazathioprine 50mgnational pharmaceutical pricing authoritynpparpg life sciencesimmunosuppressantazoran 50mgpharmatracscheduled formulation
Farhat Nasim
Farhat Nasim

    Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Aspirin in Primary Prevention of Stroke-Review of Evidence Through the Needs of Indian Clinical Settings

    Aspirin in Primary Prevention of Stroke-Review of Evidence Through the Needs of Indian Clinical...

    Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings

    Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings

    Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension, Dyslipidemia, and Familial ASCVD Risk

    Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension,...

    Featured image representing thinking

    Is Pharma Marketing Going Through "Thinking Recession"?

    Beyond BMI: Why Pioglitazone Deserves a Place in Managing Thin-Fat Type 2 Diabetes in India

    Beyond BMI: Why Pioglitazone Deserves a Place in Managing 'Thin-Fat' Type 2 Diabetes in India

    View All

    Journal Club Today

    Decades After Diagnosis, Childhood Cancer Survivors Still Vulnerable to Severe COVID: Study Shows

    Decades After Diagnosis, Childhood Cancer Survivors Still Vulnerable to Severe COVID: Study Shows

    View All

    Health News Today

    Health Bulletin 7/July/ 2025

    Health Bulletin 7/July/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok